Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
GLAXO.NS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
9.71
vs NA
Q1.23
N/A
7.88
vs NA
Q2.23
N/A
7.81
vs NA
Q3.23
N/A
12.84
vs NA
Q4.23
+2%
9.89
vs 9.71
Q1.24
-98%
0.14
vs 7.88
Q2.24
+38%
10.76
vs 7.81
Q3.24
+16%
14.91
vs 12.84
Q4.24
+37%
13.57
vs 9.89
Q1.25
+8467%
11.66
vs 0.14
Sales Growth
YoY
Current
Estimates
Q1.23
-3%
7.9B vs 8.1B
Q2.23
+2%
7.6B vs 7.5B
Q3.23
+4%
9.6B vs 9.2B
Q4.23
+0%
8.1B vs 8B
Q1.24
+18%
9.3B vs 7.9B
Q2.24
+7%
8.1B vs 7.6B
Q3.24
+6%
10.1B vs 9.6B
Q4.24
+18%
9.5B vs 8.1B
Q1.25
-10%
8.3B vs 9.3B
Q2.25
+0%
8.2B vs 8.1B
Return on Equity
QoQ
Q1.23
+8%
0.08
vs 0.11
Q2.23
+8%
0.08
vs 0.08
Q3.23
+14%
0.14
vs 0.08
Q4.23
+3%
0.03
vs 0.14
Q1.24
+11%
0.11
vs 0.03
Q2.24
+10%
0.1
vs 0.11
Q3.24
+15%
0.15
vs 0.1
Q4.24
NA
NA
vs 0.15
Institutionnal Ownership
Relative Strength
GLAXO.NS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
NSE
-40.60Â ( -1.18%)
Relative Strenght
Volume Buzz
-42%
Earning Acce
No
Dist 52w H.
3%Forecast
254%2025-Revenue
194%2025-EPS
123%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How GLAXO.NS compares to sector?